cl 387785 has been researched along with imatinib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hegedus, T; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Schuetz, JD; Ujhelly, O; Váradi, A; Várady, G | 1 |
Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
2 other study(ies) available for cl 387785 and imatinib
Article | Year |
---|---|
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Topics: Adenosine Triphosphatases; Animals; Cell Line; Cell Membrane; Drug Resistance, Multiple; Enzyme Inhibitors; HL-60 Cells; Humans; Insecta; Protein-Tyrosine Kinases | 2004 |
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |